Vaccine effectiveness of CanSino (Adv5-nCoV) COVID-19 vaccine among childcare workers – Mexico, March–December 2021

Collada, Vesta Louise Richardson-López; Franco, Martín Alejandro Camacho; Márquez, A; Valdez, Libny Martínez; Ceronio, Luis Enrique Castro; Cruz, Vicente Cruz; Gharpure, Radhika; Lafond, Kathryn E.; Yau, Tat S.; Azziz‐Baumgartner, Eduardo; Ávila, Mauricio Hernández

doi:10.1101/2022.04.14.22273413

Cited by 2 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Convidencia™ can produce high levels of anti-RBA, and its efficacy peaks 2 to 4 weeks after vaccination, gradually diminishing afterwards( 91 ). In addition, a study with healthcare workers showed a 48% effectiveness against PCR confirmed illness( 92 ).…”

Section: Introductionmentioning

confidence: 99%

COVID-19 vaccines: Update of the vaccines in use and under development

Marta

Nakamura²,

Aquino³

et al. 2022

Vacunas

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

COVID-19 vaccines: Update of the vaccines in use and under development

Marta

Nakamura²,

Aquino³

et al. 2022

Vacunas

View full text Add to dashboard Cite

The Omicron (B. 1.1. 529) wave in Mexico: Vaccine protection against progression to severe COVID-19 in SARS-CoV-2-infected workers (Preprint)

Hernández-Ávila¹,

Vieyra-Romero²,

Gutierrez-Diaz³

et al. 2022

Preprint

View full text Add to dashboard Cite

BACKGROUND The use of administrative and public health surveillance data has been key to follow the Omicron wave during the COVID-19 pandemic. Mexico is among the countries with the most registered deaths during the pandemic and few studies in the region have focused on the effect that the Omicron wave had on hospitalization and death among workers. OBJECTIVE To assess the protection of 7 different COVID-19 vaccine products against progression to severe illness, using administrative and surveillance data of private-sector workers infected with SARS-CoV-2 during the Omicron wave in Mexico from January 2 to March 5, 2022. METHODS We conducted a retrospective cohort evaluation using Respiratory-Disease Short-Term Disability Claims (RD-STDC) registered by the Mexican Social Security Institute (IMSS), linked to COVID-19 surveillance system records and the national COVID-19 vaccination registry. Among all workers who requested RD-STDC and tested positive for SARS-CoV-2, we identified those who developed illness progression (hospitalization or death) attributable to respiratory disease. Vaccinated workers were those who had received the second of a two-dose COVID-19 vaccine series or a single dose of a one-dose product ≥14 days before a positive SARS-CoV-2 test result. We estimated risk ratios for disease progression by vaccination status using Poisson regression models adjusted for sex, age, past RD-STDC, self-reported comorbidities, income, state of residency, and weekly COVID-19 incidence (RRadj). RESULTS During January 2 to March 5, 2022, n=1,410,675 (7%) among 20.1 million private sector workers requested RD-STDC, of which 31.6% had a SARS-CoV-2 test and 445,404 (92.3%) tested positive. Of these workers, 38,676 (11.1%) were unvaccinated and 309,223 (88.9%) received a complete vaccination schedule ≥ 14 days before RD-STDC; 1,198 were hospitalized, and 187 died. Risk of both hospitalization and death were lower among vaccinated persons compared with unvaccinated persons; overall RRadj for hospitalization and death were 0.36 (95% CI 0.32–0.41) and 0.24 (0.17–0.33), respectively. By product, the RRadj for hospitalization was 0.27 (95% CI 0.22–0.33) for Pfizer BioNTech; 0.29 (95% CI 0.15–0.57) for Moderna; 0.32 (95% CI 0.25–0.41) for Sinovac; 0.39 (95% CI 0.34–0.46) for Astra Zeneca; 0.39 (95% CI 0.28–0.53) Sputnik; 0.41 (95% CI 0.24–0.7) for CanSino; and 0.53 (95% CI 0.39–0.72) for Janssen. The RRadj for death was 0.12 (95% CI 0.07–0.19) for Pfizer BioNTech; 0.15 (95% CI 0.06–0.38) for Sputnik; 0.29 (95% CI 0.16–0.53) for Sinovac; 0.30 (95% CI 0.20–0.44) for Astra Zeneca; 0.38 (95% CI 0.1–1.4) for CanSino; and 0.50 (95% CI 0.26–0.97) for Janssen. CONCLUSIONS COVID-19 vaccines were associated with a significant reduction in the risk for progression to severe illness during the Omicron wave in Mexico.

show abstract

Vaccine effectiveness of CanSino (Adv5-nCoV) COVID-19 vaccine among childcare workers – Mexico, March–December 2021

Cited by 2 publications

References 31 publications

COVID-19 vaccines: Update of the vaccines in use and under development

COVID-19 vaccines: Update of the vaccines in use and under development

The Omicron (B. 1.1. 529) wave in Mexico: Vaccine protection against progression to severe COVID-19 in SARS-CoV-2-infected workers (Preprint)

Contact Info

Product

Resources

About